Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Albiges says obesity and being overweight are established risk factors to develop RCC. Conversely, patients that are overweight typically have smaller tumors and have better outcomes.

This study looked at approximately 4000 patients with mRCC treated with systemic therapy. It was confirmed that patients with high BMI were more likely to have a longer overall survival, longer time to treatment failure, and better tumor shrinkage, compared with patients with low or normal BMI.

View more from the 2015 GU Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC